The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

A woman in New York City has no detectable HIV 14 months after stopping antiretroviral therapy following a transplant of HIV-resistant stem cells, according to a presentation yesterday at the ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

Mpox (formerly known as monkeypox) can be much more severe in people living with HIV who have a very low CD4 count – so much so that some experts are calling for it to be classified as an ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

Last year, a 66-year-old Californian woman, diagnosed with HIV in 1992, appeared in a local magazine as “The World’s First Known Person Who Naturally Beat HIV.” Loreen Willenberg had always been an ...

A woman in Barcelona has maintained an undetectable HIV viral load for more than 15 years after stopping antiretroviral therapy, according to a case report presented on Friday at the 24th ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

An Israeli biotech company has issued a misleading press release which has encouraged some media outlets to falsely suggest that a new drug, Gammora, may be able to cure HIV.

Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune cells, was associated with delayed HIV rebound or sustained low viral load in a majority of people who interrupted ...

Janssen pharmaceuticals, the research branch of Johnson & Johnson, said yesterday that they were "disappointed" that the latest HIV candidate vaccine, and the only one left in a phase III efficacy ...